154 related articles for article (PubMed ID: 35654240)
21. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
[TBL] [Abstract][Full Text] [Related]
23. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
Ababneh E; Nosé V
Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
[TBL] [Abstract][Full Text] [Related]
24. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.
Uljanovs R; Sinkarevs S; Strumfs B; Vidusa L; Merkurjeva K; Strumfa I
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805976
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.
Zhu R; Wang Z; Hu Y
Clin Endocrinol (Oxf); 2020 Apr; 92(4):295-302. PubMed ID: 31945198
[TBL] [Abstract][Full Text] [Related]
27. Filamin A and parafibromin expression in parathyroid carcinoma.
Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
29. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
30. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.
Zheng HC; Takahashi H; Li XH; Hara T; Masuda S; Guan YF; Takano Y
Virchows Arch; 2008 Feb; 452(2):147-55. PubMed ID: 18080135
[TBL] [Abstract][Full Text] [Related]
31. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
Cetani F; Marcocci C; Torregrossa L; Pardi E
Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinomaT.
Pyo JS; Cho WJ
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30926677
[TBL] [Abstract][Full Text] [Related]
33. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
Kruijff S; Sidhu SB; Sywak MS; Gill AJ; Delbridge LW
Ann Surg Oncol; 2014 Feb; 21(2):426-33. PubMed ID: 24081804
[TBL] [Abstract][Full Text] [Related]
34. Loss of parafibromin expression in a subset of parathyroid adenomas.
Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
[TBL] [Abstract][Full Text] [Related]
35. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.
Tominaga Y; Tsuzuki T; Matsuoka S; Uno N; Sato T; Shimabukuro S; Goto N; Nagasaka T; Uchida K
World J Surg; 2008 May; 32(5):815-21. PubMed ID: 18338208
[TBL] [Abstract][Full Text] [Related]
36. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.
Silva-Figueroa AM; Bassett R; Christakis I; Moreno P; Clarke CN; Busaidy NL; Grubbs EG; Lee JE; Perrier ND; Williams MD
Endocr Pathol; 2019 Dec; 30(4):285-296. PubMed ID: 31734935
[TBL] [Abstract][Full Text] [Related]
37. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
Delellis RA
Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid Carcinoma: Diagnosis and Clinical Implications.
Duan K; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():80-97. PubMed ID: 26177319
[TBL] [Abstract][Full Text] [Related]
39. Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.
Popow M; Kaszczewska M; Góralska M; Kaszczewski P; Skwarek-Szewczyk A; Chudziński W; Jażdżewski K; Kolanowska M; Bogdańska M; Starzyńska-Kubicka A; Gałązka Z
Am J Case Rep; 2022 Oct; 23():e936135. PubMed ID: 36271606
[TBL] [Abstract][Full Text] [Related]
40. Understanding the genetic basis of parathyroid carcinoma.
Gill AJ
Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
